Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases

Mario Bignardi, Piera Navarria, Pietro Mancosu, Luca Cozzi, Antonella Fogliata, Angelo Tozzi, Simona Castiglioni, Carlo Carnaghi, Maria Chiara Tronconi, Armando Santoro, Marta Scorsetti

Research output: Contribution to journalArticlepeer-review


Purpose: We report the medium-term clinical outcome of hypofractionated stereotactic body radiotherapy (SBRT) in a series of patients with either a solitary metastasis or oligometastases from different tumors to abdominal lymph nodes. Methods and Materials: Between January 2006 and June 2009, 19 patients with unresectable nodal metastases in the abdominal retroperitoneal region were treated with SBRT. Of the patients, 11 had a solitary nodal metastasis and 8 had a dominant nodal lesion as part of oligometastatic disease, defined as up to five metastases. The dose prescription was 45 Gy to the clinical target volume in six fractions. The prescription had to be downscaled by 10% to 20% in 6 of 19 cases to keep within dose/volume constraints. The first 11 patients were treated with three-dimensional conformal techniques and the last 8 by volumetric intensity-modulated arc therapy. Median follow-up was 1 year. Results: Of 19 patients, 2 had a local progression at the site of SBRT; both also showed concomitant tumor growth at distant sites. The actuarial rate of freedom from local progression was 77.8% ± 13.9% at both 12 and 24 months. Eleven patients showed progressive local and/or distant disease at follow-up. The 12- and 24-month progression-free survival rates were 29.5% ± 13.4% and 19.7% ± 12.0%, respectively. The number of metastases (solitary vs. nonsolitary oligometastases) emerged as the only significant variable affecting progression-free survival (p <0.0004). Both acute and chronic toxicities were minimal. Conclusions: Stereotactic body radiotherapy for metastases to abdominal lymph nodes was shown to be feasible with good clinical results in terms of medium-term local control and toxicity rates. Even if most patients eventually show progressive disease at other sites, local control achieved by SBRT may be potentially significant for preserving quality of life and delaying further chemotherapy.

Original languageEnglish
Pages (from-to)831-838
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Issue number3
Publication statusPublished - Nov 1 2011


  • IMRT
  • Lymph node metastases
  • RapidArc
  • SBRT
  • Volumetric modulated arc therapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research


Dive into the research topics of 'Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases'. Together they form a unique fingerprint.

Cite this